Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population
Participants in the uproleselan arm had a median overall survival of 13 months vs. 12.3 months in the placebo arm.
Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm.
https://finance.yahoo.com/news/glycomimetics-announces-results-pivotal-phase-100000750.html
ほんとだー。
Study of uprole…
2024/05/06 22:37
Study of uproleselan combined with chemotherapy did not meet its primary endpoint of overall survival in the intent to treat population Participants in the uproleselan arm had a median overall survival of 13 months vs. 12.3 months in the placebo arm.